1. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. Issue 4 (17th October 2008) Authors: Honnorat, J; Cartalat-Carel, S; Ricard, D; Camdessanche, J Ph; Carpentier, A F; Rogemond, V; Chapuis, F; Aguera, M; Decullier, E; Duchemin, A M; Graus, F; Antoine, J C Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 80:Issue 4(2009) Page Start: 412 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P01.041 Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma. (19th September 2018) Authors: Le Rhun, E; Devos, P; Houillier, C; Cartalat-Carel, S; Chinot, O; Di Stefano, A; Reyns, N; Dubois, F; Weller, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗